Research CombinationFat LossPreclinical EvidenceEducational · Not medical advice
Semaglutide + Tesamorelin: Targeted Fat Loss
A dual-mechanism fat loss stack combining semaglutide's appetite suppression and GLP-1-mediated metabolic benefits with tesamorelin's targeted visceral fat reduction through GHRH agonism. Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity, while tesamorelin specifically mobilises deep abdominal visceral adipose tissue by stimulating pulsatile GH release. The two agents operate through entirely non-overlapping pathways and address different fat compartments.
- 2
- Compounds
- Preclinical
- Evidence Level
- 3
- Research Refs
- Fat Loss
- Primary Goal
Mechanism
Compound 1Fat Loss
Semaglutide
Reduces appetite and caloric intake via GLP-1 receptor agonism, improves insulin sensitivity, and drives broad body composition improvements — serving as the primary overall fat loss driver of the stack.
+
+
Compound 2Fat Loss
Tesamorelin
Specifically targets visceral adipose tissue via GHRH-stimulated GH pulses that preferentially mobilise deep abdominal fat, addressing a metabolically harmful fat depot that GLP-1 agonism alone may not fully resolve.
Synergistic Effect
Dual-pathway activation
Semaglutide × Tesamorelin
Safety Notes
Semaglutide is an FDA-approved prescription GLP-1 agonist carrying a boxed warning for thyroid C-cell tumour risk (observed in rodents; human risk not established). It requires a licensed prescriber and is contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; its use for general fat loss is off-label and outside its approved indication. This is a prescription-only combination not appropriate for unsupervised use.
Research References
Established
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial)
NEJM 2021PMID 33567185
Established
Effects of tesamorelin (TH9507) in HIV-infected patients with abdominal fat accumulation
J Acquir Immune Defic Syndr 2010PMID 20616699
Established
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patients
Lancet HIV 2019PMID 31285190
MOTS-c + SS-31: Mitochondrial Optimization
Anti-AgingFat LossEmergingA mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.
AOD-9604 + Tirzepatide: Advanced Body Composition
Fat LossPreclinicalAOD-9604, a C-terminal fragment of human growth hormone associated with selective lipolytic activity, is paired with Tirzepatide's dual GIP and GLP-1 receptor agonism for appetite regulation and energy balance. The combination is explored for addressing fat reduction through complementary peripheral and central mechanisms.
Hexarelin + Mod GRF 1-29: Anabolic GH Amplification
Muscle GrowthFat LossPreclinicalHexarelin is one of the most potent synthetic GHRP compounds, associated with robust GH release and additional cardioprotective receptor activity. Mod GRF 1-29 (CJC-1295 without DAC) is a truncated GHRH analog that provides pulsatile GH stimulation without pituitary desensitization. This pairing is commonly researched for maximizing GH secretion through complementary GHRH and GHRP receptor activation.
⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.